What if cancer immunotherapy response rates could be improved by just 10%? In this webinar clip, our team discusses the potential impact of $SONA $SNANF gold nanorod THT therapy across multiple cancer types: youtu.be/MeZPEVdV8JU

$SONA $SNANF announces that a first dosing has been achieved in the previously announced early feasibility study of its Targeted Hyperthermia Therapy cancer treatment. Read the full news release here: bit.ly/4lMmBxv

Catch the latest Proactive Investors interview recapping our recent milestone: dosing the first patient in our Targeted Hyperthermia Therapy trial for advanced melanoma. Hear from CEO, David Regan, on what’s next for $SONA $SNANF: bit.ly/44wSd30

Join $SONA $SNANF CEO & CMO for a live investor webinar, on which they will discuss the first patient dosing in the current first-in-human clinical trial of Sona’s THT cancer therapy. Register today: bit.ly/4kA03yT

Join $SONA $SNANF for a live webinar as they discuss the first patient dosing in Sona’s first-in-human clinical trial of its THT cancer therapy. Featuring guest panelist, immunologist, Dr. Conrad, Head of the division of hematopathology at IWK Health.: bit.ly/4kA03yT

Join $SONA $SNANF today for a webinar as they discuss the first patient dosing in Sona’s first-in-human clinical trial of its THT cancer therapy. Featuring guest panelist, immunologist, Dr. Conrad, Head of the division of hematopathology at IWK Health.: bit.ly/4kA03yT

Get insights on $SONA $SNANF & the progress with their first-in-human cancer treatment clinical trial in this replay of yesterday's webinar. Hear directly from their CEO & CMO, as well as an expert panelist.: bit.ly/4kOvOEy

$SONA $SNANF has received Nova Scotia Health Research Ethics Board approval to conduct its proposed pilot human clinical trial study of its Targeted Hyperthermia Therapy cancer treatment with late-stage melanoma patients.  Read the full news release: bit.ly/4lKEfSB

$SONA $SNANF CEO David Regan sat down with Proactive Investors to discuss our second ethics approval a trial of our cancer therapy with late-stage human melanoma and what this means for Sona. Watch the full interview: bit.ly/4mdgO4b

Episode 4 of Carman’s Corner is here! Dr. Carman delves into the fundamentals of immunotherapy, how modern medicine empowers the immune system to fight cancer. Learn how science is unlocking new possibilities in cancer treatment.

$SONA $SNANF | Proactive Investors recently featured an article on Sona’s THT, which converts “cold” tumours into “hot” tumours to enhance response to cancer immunotherapy. Early clinical trials are underway, with larger studies planned. Read more: bit.ly/4m4ZBdG

$SONA Nanotech has completed treatment for the first cohort in its first-in-human early feasibility study of Targeted Hyperthermia Therapy for late-stage melanoma. No significant adverse health events observed. With full results expected this fall. bit.ly/4lKhOfy

Episode 5 of Carman’s Corner is out! Dr. Carman Giacomantonio explains how immune checkpoints impact cancer treatment—and how Sona is tackling the challenges of immunotherapy. Watch here 👇

$SONA CEO David Regan joins 3,500+ medtech leaders at #MedTechConference, sponsored by Abbott, BD, Johnson & Johnson MedTech, and Medtronic. Sona’s THT is redefining cancer treatment with a gentle, immune-activating nanotechnology. #MedTech #Nanomedicine #SonaNanotech

Dr. Carman Giacomantonio shares how $SONA’s targeted hyperthermia therapy could change the game by helping immune cells better recognize cancer. Watch the latest episode now! bit.ly/4pZTHg8 #CancerImmunotherapy #SonaNanotech

$SONA announces that it will host a webinar on Monday, October 20th at noon EDT to discuss its first-in-human, early feasibility clinical study for its Targeted Hyperthermia Therapy cancer treatment. Register for the webinar here: bit.ly/4oiug7G

$SONA announces completion of its first-in-human study treating patients with immunotherapy-resistant metastatic melanoma using THT. By day 15, 8/10 patients showed significant response; 6/8 had no detectable residual melanoma. bit.ly/4ouTSi2

$SONA announces completion of its first-in-human study using THT in immunotherapy-resistant metastatic melanoma. By day 15, 8/10 patients showed significant response; 6/8 had no detectable melanoma. 📢 Join our webinar today at 12 PM EDT to learn more: bit.ly/4oiug7G

Webinar Replay Now Available Hear $SONA CEO David Regan & CMO Dr. Carman Giacomantonio discuss promising first-in-human results for our Targeted Hyperthermia Therapy (THT) in late-stage melanoma and what’s next. bit.ly/4qlzOQP #SonaNanotech #Biotech #cancerresearch

Sona Nanotech CEO David Regan joins @Proactive to discuss 8/10 patient responses, including 6 complete, in our first-in-human THT cancer study. Next: Health Canada trial + broader applications. 🎥 Watch: bit.ly/4nfCJYy $SONA #CancerTherapy #Biotech #Immunotherapy